---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021347"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-08-05T23:59:59+00:00"
generated_at: "2026-06-24T03:25:34.501068+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcutis Biotherapeutics closes underwritten public offering of 8.625M shares at $20, net proceeds ~$161.7M

## Summary
- Sold 7.5M shares plus full exercise of over-allotment of 1.125M shares at $20 per share.
- Net proceeds approximately $161.7M after underwriting discounts and expenses.
- Proceeds to fund development, approval, commercial launch for ZORYVE and general corporate purposes.
- Underwriters include Morgan Stanley, Cowen, Guggenheim Securities.

## SEC filing metadata
- accession: 0001628280-22-021347
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828022021347/0001628280-22-021347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828022021347/arqt-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021347
- JSON: https://secwatch.observer/filing/0001628280-22-021347.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.